Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Project Oncology®
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Shelina Ramnarine, PhD; John Mascarenhas, MD
- Shelina Ramnarine, PhD
- John Mascarenhas, MD
- Marina Kremyanskaya, MD
Gastric Cancer Prevention: A Risk-Based Approach
Gastric Cancer Prevention: A Risk-Based Approach
GI Insights
Gastric Cancer Prevention: A Risk-Based Approach
Peter Buch, MD, FACG, AGAF, FACP; Chul Hyun, MD, PhD, MPH
- Peter Buch, MD, FACG, AGAF, FACP
- Chul Hyun, MD, PhD, MPH
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Project Oncology®
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Charles Turck, PharmD, BCPS, BCCCP; Douglas A. Tremblay, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Douglas A. Tremblay, MD
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Project Oncology®
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Steve Jackson, PharmD; Apar Kishor Ganti, MD
- Steve Jackson, PharmD
- Apar Kishor Ganti, MD
- Thomas Marron, MD, PhD
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
MinuteCE®
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
Axatilimab’s Impact on cGVHD and Associated BOS
Axatilimab’s Impact on cGVHD and Associated BOS
Project Oncology®
Axatilimab’s Impact on cGVHD and Associated BOS
Charles Turck, PharmD, BCPS, BCCCP; Amandeep Salhotra, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Amandeep Salhotra, MD
CME/CE Virtual Event
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Multiple dates available
0.75 credits

Medical News

Medical News
Mental Health Comorbidity Raises Acute Care Use in Cancer
08/17/2026
Read more
Medical News
BACE Added to Tislelizumab Improved Response in Bulky NSCLC
08/17/2026
Read more
Medical News
CT Body Composition Misses Cancer Nutritional Risk
08/17/2026
Read more
Medical News
SEER-22 Study Finds Mycosis Fungoides Survival Gaps
08/11/2026
Read more

CME/CE

MinuteCE®
Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 credit 5 episodes
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 credit 5 episodes
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
CME/CE In-Person & Virtual Event
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026
New Orleans, Louisiana
1.50 credits

Clinical Practice

CME/CE Virtual Event
Targeting TROP2 in EGFR-Mutated Advanced NSCLC: Navigating the ADC Revolution After TKI Failure
Multiple dates available
0.50 credits
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
Real-World Outcomes with Axatilimab in cGVHD
Real-World Outcomes with Axatilimab in cGVHD
Project Oncology®
Real-World Outcomes with Axatilimab in cGVHD
Brian P. McDonough, MD, FAAFP; Hana Safah, MD
- Brian P. McDonough, MD, FAAFP
- Hana Safah, MD
First-Line Treatment Considerations in Advanced Urothelial Carcinoma
First-Line Treatment Considerations in Advanced Urothelial Carcinoma
Project Oncology®
First-Line Treatment Considerations in Advanced Urothelial Carcinoma
Guru P. Sonpavde, MD
- Guru P. Sonpavde, MD

Programs

Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
CME/CE
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Amer Zeidan, MBBS; Ghayas Issa, MD
0.50 credits
- Amer Zeidan, MBBS
- Ghayas Issa, MD
0.50 credits
Current Approaches to Advanced Urothelial Carcinoma
Current Approaches to Advanced Urothelial Carcinoma
Project Oncology®
Current Approaches to Advanced Urothelial Carcinoma
Guru P. Sonpavde, MD
- Guru P. Sonpavde, MD
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Project Oncology®
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Guru P. Sonpavde, MD
- Guru P. Sonpavde, MD
Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Project Oncology®
Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance